pyrroloquinoline

Small moleculeexperimental

Clinical trial activity

4 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0

Earliest trial started Jan 27, 2024 (NCT06431113)

Timeline

2020s

  1. Jan 1, 2024

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2024

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06748989N/AFeb 1, 2025FEMPHARMA Kft.
NCT06245083Early Phase 1 (Phase 1)Dec 31, 2024University of Oklahoma
NCT07148726N/ASep 1, 2024University of Padova
NCT06431113Phase 3Jan 27, 2024University of Naples Frederico II, University of Pavia, University of Roma La Sapienza
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
FEMPHARMA Kft.For profit1112025
University of Naples Frederico IIAcademic/Hospital1012024
University of OklahomaAcademic/Hospital1112024
University of PadovaAcademic/Hospital1112024
University of PaviaAcademic/Hospital1112024
University of Roma La SapienzaAcademic/Hospital1012024
6 organizations
Page 1 / 1